HighTower Advisors LLC Acquires Shares of 25,500 Leap Therapeutics, Inc. (NASDAQ:LPTX)

HighTower Advisors LLC bought a new position in Leap Therapeutics, Inc. (NASDAQ:LPTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,500 shares of the company’s stock, valued at approximately $65,000.

A number of other large investors have also made changes to their positions in the company. Valence8 US LP acquired a new position in Leap Therapeutics in the 3rd quarter worth approximately $48,000. Marshall Wace LLP boosted its position in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock worth $156,000 after buying an additional 58,094 shares during the period. Key Client Fiduciary Advisors LLC grew its holdings in shares of Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after buying an additional 37,067 shares in the last quarter. Finally, Simplify Asset Management Inc. raised its position in Leap Therapeutics by 67.9% during the second quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock valued at $1,237,000 after buying an additional 255,293 shares during the period. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Stock Up 2.4 %

Shares of NASDAQ:LPTX opened at $2.98 on Friday. The firm has a fifty day moving average of $3.11 and a two-hundred day moving average of $2.63. Leap Therapeutics, Inc. has a 12-month low of $1.68 and a 12-month high of $5.00. The firm has a market capitalization of $114.19 million, a P/E ratio of -1.54 and a beta of 0.21.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $5.50 price objective on shares of Leap Therapeutics in a research report on Friday, November 15th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.